SCHOLAR ROCK HOLDING CORPORATION Income (Loss) from Continuing Operations before Income Taxes, Domestic
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$377.73 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-03
- SCHOLAR ROCK HOLDING CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$377.73M.
- SCHOLAR ROCK HOLDING CORPORATION income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$246.29M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$377.73M 10-K · filed 2026-03-03 |
| 2024-12-31 | -$246.29M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |